Last week, we organised an Expert Access event on multiple sclerosis (MS) with the participation of Dr Géraldine Androdias, a neurologist at Lyon University Hospital. Dr Androdias presented the key points of the ECTRIMS 2024 conference, as well as new trends in treating the illness. We note an unmet need in the primary progressive and secondary progressive forms, a real interest for the BTKi class with the greater penetration of the blood-brain barrier, and expectations for the anti-C...
Nous avons organisé la semaine dernière un Expert Access autour de la sclérose en plaques (SEP) avec la participation du Dr Géraldine Androdias, médecin neurologue au CHU de Lyon. Le Dr Androdias a présenté les points saillants du congrès de l’ECTRIMS 2024 ainsi que les nouvelles tendances dans la prise en charge de la maladie. Nous retenons un besoin insatisfait dans les formes progressives et secondairement progressives, un vrai intérêt de la classe des BTKi avec le passage accru de...
>Q3 2024 broadly in line with forecasts, encouraging despite a high comparison base - Yesterday before market open, IHG reported a current trading Q3 2024 broadly in line with our forecasts, giving RevPaR growth of +1.5%, of which +1.7% in the Americas region (including +1.2% in the US), +4.9% in EMEAA and a decline of 10.3% in Greater China, impacted notably by a tough comparison base (Q3 2023 RevPAR at +9.3% vs 2019). Moreover, the end of the license contract for th...
>T3 24 globalement en ligne avec les attentes, encourageant malgré une base de comparaison élevée - IHG a publié hier avant Bourse un current trading T3 24 globalement en ligne avec nos attentes, soit une croissance des RevPAR de +1.5%, dont +1.7% dans la région Amériques (incl. +1.2% aux US), +4.9% en EMEAA et un recul de 10.3% en Greater China, impacté notamment par une base de comparaison difficile (RevPAR T3 23 à +9.3% vs 2019). Par ailleurs, la fin d’un contrat d...
>Q3 2024 trading update broadly in line with our expectations - IHG has just released its Q3 2024 trading update with RevPAR up 1.5% y-o-y, broadly in line with our expectations (ODDO BHF +1.6%e) and being an unsurprising sequential slowdown after +3.0% in H1 2024, given a tougher comparison base in Q3. This is driven by price, at +1.7% y-o-y whereas the occupancy rate was almost flat (-0.1pts). In detail, Q3 2024 RevPAR by region (y-o-y): 1/ Americas: +1.7% (ODDO BHF...
>Q3 2024 trading update broadly in line with our expectations - IHG has just released its Q3 2024 trading update with RevPAR up 1.5% y-o-y, broadly in line with our expectations (ODDO BHF +1.6%e) and being an unsurprising sequential slowdown after +3.0% in H1 2024, given a tougher comparison base in Q3. This is driven by price, at +1.7% y-o-y whereas the occupancy rate was almost flat (-0.1pts). In detail, Q3 2024 RevPAR by region (y-o-y): 1/ Americas: +1.7% (ODDO BHF...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.